6 Chinese medicine enterprises have less than 1% of their revenue in research and development investment

Medical Network May 20 hearing Flush medical and biological medicine sector a total of 68 listed companies, 67 have been released 2019 Annual Report, ST Kang Mei (Hong Mei medicine) just released 2019 key operating results, the annual report will be delayed to released in JuneAmong them, eight companies suffered losses due to the most serious financial fraud that have been subject to heavy penalties ST Kang of the United Statesloss of eight companies were ST Combibloc, Kyrgyzstan drug Holdings, donkey-hide gelatin, cream pharmaceuticals, Conba, Jiaying Pharmaceutical, Taiji Group, Longjin Pharmaceutical and country issued shares, most of the loss is Hong Mei STST Kang US released data show that in 2019 the main business during the reporting period, the company achieved revenues of 11.263 billion yuan, down 36.07 percent; attributable to shareholders of listed companies net profit -36.48 billion yuan, down 1,057.10 percentwas established in 1997, Health America Pharmaceutical Chinese Herbal Medicine-based products, listed in 2001, was a white horseA shares, the market value was over hundreds of billions2018, Health America Pharmaceutical controversy, the question of financial fraud and corporate real control price manipulation and other peopleDecember 2018, China Securities Regulatory Commission found during the daily supervision of the US pharmaceutical alleged false statements and other financial reports, then its criminal investigationMay 15, Health America Pharmaceutical announcement shows the company's financial fraud case investigation, trial end, China Securities Regulatory Commission finds that the US pharmaceutical four major financial fraud illegal facts, in fact, control of the company and people , executives and other punishable by 100,000 yuan -90 million in penalties, and Ma Xingtian, Qiuxi Wei Xu Dongjin couple and lifelong security market to take measures to take 10-year securities market exclusion measures Zhuang Yiqing, Wenshao Sheng, Ma Huanzhoumedicinelow R & D investment has been criticized2019, Chinese medicine research and development investment accounted for only a median revenue ratio was 3.28%, in addition to three companies unpublished research data, only 33 Chinese enterprises to achieve / exceed this level, accounting for revenue ratio of R & D investment over 10% only two, namely Longjin Pharmaceutical and Hong edge medicineAmong them, Longjin Pharmaceutical R & D investment 29,300,500 yuan, accounting for revenue ratio of 10.64%; Hong edge medicine R & D investment 465 million yuan, accounting for revenue ratio was 10.18%there are 32 Chinese companies R & D investment of 3.28% below the median ofAmong them, Baiyun Mountain, Dali medicine, Tai Tong, Yunnan Baiyao, the letter states pharmacy, the country issued shares of total revenues, R & D investment ratio did not exceed 1%"Chinese enterprises R & D investment growth year on year, after half of the traditional Chinese medicine research and development investment less than 1%." Ding Chen Beijing Center for Pharmaceutical Management Consulting Shili Chen pointed out that the new drug prescription needed doing clinical trials, or can not pass, forced enterprises have to increase R & D investment"Because the homogenization of too much competition, some of the Chinese companies take the initiative to strengthen research and development to enhance their market competitiveness, optimize the product structure In addition, herbal medicine research and development direction is a global trend, many companies are willing to invest in plant medicine research and development."


68 companies selling expenses as a percentage of revenue than the median was 34.29 percent, over the median total of 34 enterprises, Longin pharmaceutical, Dali medicine, Jiaying pharmaceutical three companies sales expenses as a percentage of revenue ratio over 60% Among them, Longin Jiaying Pharmaceutical Pharmaceutical and are at a loss, net profit was -2310.74 million -1.22 million cost of sales is the highest step pharmaceuticals, up 8.081 billion yuan, accounting for its revenue ratio was 56.68%, down slightly from 2018 Selling expenses Dali Pharmaceutical 1.84 billion, though fell 32%, cost of sales for the first time after Dali medicine on the market lower, but still accounting for revenue ratio up to 62.59% While research and development costs of only 2.2305 million yuan, accounting for 0.76% of revenue Dali Pharmaceutical in the annual report explained that in 2019, by the New Deal regulatory medicine, medicine circulation system reform and the impact of the Medicare drug control policy fees, product sales decline, to retain the existing market share, the company's ongoing marketing efforts Shili Chen said that in the case of public mainly to Western medicine, Chinese medicine business sales more difficult than Western medicine, companies need to invest more in marketing costs "Chinese medicine sales not only in public hospitals to market-based policy efforts, , the clinic also strive to expand its channels, but two more channels required profits, so sales costs will increase."